ART4 and infection: The heightened neutralization breadth seen after Omicron BA.4/BA.5 breakthrough infection suggested that variant-adapted vaccines based on the Omicron BA.4/5 S glycoprotein sequence may elicit a recall response with broader cross-neutralization than those based on Omicron BA.1.